Foralumab has not yet received final commercial marketing approval from the United States Food and Drug Administration (FDA) or international regulatory bodies as a widely available prescription drug. It remains an investigational therapeutic candidate currently undergoing rigorous clinical evaluations, including Phase 2 clinical trials and expanded access programs for neurodegenerative diseases like secondary progressive multiple sclerosis, Alzheimer's disease, and multiple system atrophy.